Levels of expression of p27(KIP1) protein in human prostate and prostate cancer: An immunohistochemical analysis

Modern Pathology

Volumn 12, Issue 8, 1999, Pages 751-755

  Erdamar, Sibel ^a   Yang, Guang ^a   Harper, J Wade ^a   Lu, Xin ^b   Kattan, Michael W ^a   Thompson, Timothy C ^a   Wheeler, Thomas M ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

Immunohistochemistry; P27(KIP1); Prostate cancer

Indexed keywords

AVIDIN; BIOTIN; CYCLIN DEPENDENT KINASE; FORMALDEHYDE; MONOCLONAL ANTIBODY; PARAFFIN; PROTEIN P27; CELL CYCLE PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENZYME INHIBITOR; MICROTUBULE ASSOCIATED PROTEIN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER STAGING; CELL PROLIFERATION; COLON CARCINOMA; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN EXPRESSION; BIOSYNTHESIS; DISEASE COURSE; DRUG ANTAGONISM; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYCLIN-DEPENDENT KINASES; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROSTATE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 0032588872     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Murakami MS, Strobel MC, Woude GFV. Cell cycle regulation, oncogenes, and antineoplastic drugs. In: Mendelson J, Howley P, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia: Saunders; 1995. p. 3-10.
2. Elledge SJ, Winston J, Harper JW. A question of Balance: The roles of cyclin kinase inhibitors in development and tumorigenesis. Trends Cell Biol 1996;6:388-92.
3. Harper JW. Cyclin-dependent kinase inhibitors. Cancer Surv 1997;29:91-107.
4. Sherr CJ, Roberts JM. Mammalian cyclin-dependent kinase inhibitors. Genes Devel 1995;9:1149-63.
5. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
6. KIP2 alters differentiation and cell proliferation in multiple tissues and plays a role in Beckwith-Wiedemann syndrome. Nature 1997;387:151-8.
7. KIP2 in the control of tissue growth and development. Genes Devel 1998;12:3162-7.
8. Zhang P, Wong C, Finegold M, Harper JW, Elledge SJ. p21 and p57 control muscle differentiation at the myogenin step. Genes Devel 1999;13:213-24.
9. Yasui W, Kudo Y, Semba S, Yokozoki H, Tahara E. Reduced expression of cyclin-dependent kinase inhibitor p27 is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res 1997;88:625-9.
10. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med 1997;3:231-4.
11. Tan P, Cady B, Wanner M, Worland P, Cukor B, Magi-Galluzzi C, et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas: Cancer Res 1997;57:1259-63.
12. Esposito V, Baldi A, De Luca A, Groger AM, Loda M, Giordano GG, et al. Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer: Cancer Res 1997;57:3381-5.
13. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncary L, Sandhu C, et al. Decreased levels of the cell cycle inhibitor p27 protein: prognostic implications in primary breast cancer. Nat Med 1997;3:227-30.
14. Yang RM, Naitoh J, Murphy M, Wang H, Phillipson J, Dekernion JB, et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 1998; 159:941-5.
15. Tsihlias J, Kapusta LR, DeBoer G, Morova-Protzner I, Zbieranowski I, Bhattcharya N, et al. Loss of cyclin-dependent kinase inhibitor p27 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
16. KIP1 in prostatic adenocarcinoma. Mod Pathol 1998;11:324-8.
17. KIP1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20.
18. KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst 1998;90:1284-91.
19. KIP1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-4.
20. KIP1 is haploinsufficient for tumour suppression. Nature 1998;396:177-80.
21. KIP1 and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci U S A 1997;94:6380-5.